Filing Details
- Accession Number:
- 0001765581-22-000009
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-02-03 16:41:29
- Reporting Period:
- 2022-02-01
- Accepted Time:
- 2022-02-03 16:41:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1232524 | Jazz Pharmaceuticals Plc | JAZZ | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1193210 | C Bruce Cozadd | 5Th Fl, Waterloo Exchange Waterloo Rd Dublin 4 L2 | Chairman & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2022-02-01 | 9,700 | $46.83 | 332,160 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2022-02-01 | 2,050 | $138.11 | 330,110 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2022-02-01 | 2,136 | $139.24 | 327,974 | No | 4 | S | Direct | |
| Ordinary Shares | Disposition | 2022-02-01 | 2,186 | $140.26 | 325,788 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Non-Qualified Stock Option (right to buy) | Disposition | 2022-02-01 | 9,700 | $0.00 | 9,700 | $46.83 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 58,132 | 2022-08-08 | No | 4 | M | Direct |
Footnotes
- Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.68 to $138.631. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $138.775 to $139.70. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $139.92 to $140.52. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.
Billionaire Hedge Funds
